Stockscreener 앱 받기
6.055
4.41%
0.255
전일 마감가:
$5.80
열려 있는:
$5.84
하루 거래량:
1.04M
Relative Volume:
0.66
시가총액:
$613.75M
수익:
-
순이익/손실:
$-167.48M
주가수익비율:
-3.1051
EPS:
-1.95
순현금흐름:
$-197.47M
1주 성능:
-9.75%
1개월 성능:
-8.66%
6개월 성능:
-49.74%
1년 성능:
-52.39%
1일 변동 폭
$5.825
$6.075
1주일 범위
$5.635
$7.0399
52주 변동 폭
$5.635
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
DAWN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.055 | 697.37M | 0 | -167.48M | -197.47M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.60 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.15 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
430.86 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
672.75 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
296.29 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Q2 2025 Earnings Call Transcript - Insider Monkey
Day One Biopharma’s Earnings Call Highlights Growth and Strategy - TipRanks
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Plunges 13.95% Despite Revenue Surge - AInvest
Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate - MSN
Day One Biopharmaceuticals (DAWN): A High-Growth Biotech Play in Pediatric Oncology with a Clear Path to Value Creation - AInvest
Day One Biopharmaceuticals Inc (DAWN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Day One Biopharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Day One Biopharma Reports Strong Q2 2025 Growth - TipRanks
Day One Biopharmaceuticals' Q2 2025: Unpacking Contradictions in Treatment Durability, Financial Projections, and Growth Trajectory - AInvest
Day One Biopharmaceuticals: Scaling OJEMDA Revenue While Strengthening R&D and Financial Discipline - AInvest
Day One Biopharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Day One Biopharma Q2 2025 revenue growth impresses - Investing.com UK
Day One Biopharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Day One Biopharmaceuticals Reports Strong Q2 2025 Results - TipRanks
Day One Reports Second Quarter 2025 Financial Results and Corporate Progress - GlobeNewswire
What are analysts’ price targets for Day One Biopharmaceuticals Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
How volatile is Day One Biopharmaceuticals Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News
What is the risk reward ratio of investing in Day One Biopharmaceuticals Inc. stock - Jammu Links News
Is it the right time to buy Day One Biopharmaceuticals Inc. stockCapitalize on high-yield stock opportunities - Jammu Links News
Day One Biopharmaceuticals Inc. Stock Analysis and ForecastCapitalize on emerging trends for profits - Jammu Links News
Why is Day One Biopharmaceuticals Inc. stock attracting strong analyst attentionFree Investment Community - Jammu Links News
How does Day One Biopharmaceuticals Inc. generate profit in a changing economyTremendous growth opportunities - Jammu Links News
Is Day One Biopharmaceuticals Inc. a growth stock or a value stockBuild a portfolio that withstands market volatility - Jammu Links News
How many analysts rate Day One Biopharmaceuticals Inc. as a “Buy”Unbelievable profit margins - Jammu Links News
What are the technical indicators suggesting about Day One Biopharmaceuticals Inc.Build a portfolio that outperforms consistently - Jammu Links News
Does Day One Biopharmaceuticals Inc. stock perform well during market downturnsPhenomenal trading returns - Jammu Links News
How strong is Day One Biopharmaceuticals Inc. company’s balance sheetInvest smarter with cutting-edge analytics - Jammu Links News
What makes Day One Biopharmaceuticals Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
Can a trend reversal in Day One Biopharmaceuticals Inc. lead to recoveryYield Curve Outlook and Long-Term Implication Summary - Newser
Day One Biopharmaceuticals Inc. stock chart pattern explainedRisk/Reward Optimization Entry Point Analysis - Newser
Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025 - 富途牛牛
Published on: 2025-07-30 22:40:17 - Newser
Can Day One Biopharmaceuticals Inc. recover in the next quarterWeekly Stock Opportunity Radar Scanner Activated - metal.it
How Day One Biopharmaceuticals Inc. stock performs during market volatilityNeural Model for Stock Price Movement - Newser
Published on: 2025-07-30 04:25:27 - Newser
Trapped Investors in Day One Biopharmaceuticals Inc. Await Breakout SignalMulti-Bagger Potential Stock Forecast Tools Released - beatles.ru
How institutional ownership impacts Day One Biopharmaceuticals Inc. stockFree Short Term Buy Zone Stock Alerts - Newser
Comparing Day One Biopharmaceuticals Inc. in custom built stock radarsAsset Growth Pattern and Return Summary - Newser
Cwm LLC Acquires 21,639 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) - Defense World
Published on: 2025-07-29 09:05:06 - metal.it
Why Day One Biopharmaceuticals Inc. stock attracts strong analyst attentionStrategy Builder for Growth Focused Traders - Newser
Will Day One Biopharmaceuticals Inc. stock benefit from AI tech trendsPost Market Planner For Smart Trading - jammulinksnews.com
Is There Enough Volume to Lift Day One Biopharmaceuticals Inc.Fast Gaining Stock Screener Reports Released - metal.it
Published on: 2025-07-28 22:51:58 - metal.it
Published on: 2025-07-29 00:12:20 - beatles.ru
What is the dividend policy of Day One Biopharmaceuticals Inc. stockBoost your returns with professional guidance - Jammu Links News
Will Day One Biopharmaceuticals Inc. see short term momentumFree High Return Stock Focus With Safety - Newser
What catalysts could drive Day One Biopharmaceuticals Inc. stock higher in 2025Capital growth strategies that work - Jammu Links News
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Day One Biopharmaceuticals Inc 주식 (DAWN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Dubow Adam | GENERAL COUNSEL |
May 16 '25 |
Sale |
6.26 |
4,552 |
28,486 |
47,136 |
| York Charles N II | COO, CFO AND SECRETARY |
May 16 '25 |
Sale |
6.26 |
4,282 |
26,796 |
265,231 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
May 16 '25 |
Sale |
6.26 |
13,964 |
87,385 |
145,737 |
0.43%
1.83%
자본화:
|
볼륨(24시간):